HOMCY CHARLES J 4

What Happened

• Charles J. Homcy, a director of Maze Therapeutics (MAZE), was granted 18,000 derivative shares/options on June 8, 2026. The award shows an acquisition price of $0.00, indicating a grant rather than a purchase.

Key Details

• Transaction date: June 8, 2026; Filing date: June 10, 2026 (filed on time).
• Transaction type/code: Grant/Award (derivative security), 18,000 shares at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option/shares vest and become fully exercisable on the earlier of (i) the issuer’s 2027 annual stockholders’ meeting or (ii) June 8, 2027, provided Homcy remains in service on the vesting date.
• No 10b5-1 plan, tax-withholding sale, or immediate sale reported.

Context

• This was a compensation grant (derivative award) rather than an open-market purchase or sale. Such awards are typically part of director compensation and do not by themselves indicate a buy/sell signal; they vest in the future and require continued service to become exercisable.